Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
GNLX
Stock Latest News
Company Announcements
Genelux Announces Underwritten Public Offering to Raise Capital
8d ago
8K
GNLX
Premium
The Fly
Genelux prices 6.67M shares at $3.00 in underwritten public offering
8d ago
GNLX
Premium
The Fly
Genelux announces common stock offering, no amount given
9d ago
GNLX
Premium
The Fly
Genelux data update indicates disease early control, says H.C. Wainwright
11d ago
GNLX
Premium
Ratings
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
11d ago
GNLX
Premium
Company Announcements
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
11d ago
8K
GNLX
Premium
The Fly
Genelux reports interim data of systemic administration of Olvi-Vec
11d ago
GNLX
Premium
Company Announcements
Genelux Appoints Veteran Oncologist Jason Litten as CMO
14d ago
8K
GNLX
Premium
The Fly
Genelux appoints Jason Litten as CMO
14d ago
GNLX
Premium
Ratings
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
2M ago
GNLX
Premium
Ratings
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
2M ago
GNLX
Premium
The Fly
Genelux reports Q3 EPS (21c), consensus (21c)
2M ago
GNLX
Premium
The Fly
Genelux initiated with a Buy at Titan Partners
3M ago
GNLX
Premium
Company Announcements
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
3M ago
GNLX
Premium
Company Announcements
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
3M ago
GNLX
Premium
Ratings
Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
3M ago
GNLX
Premium
The Fly
Genelux price target raised to $20 from $10 at Maxim
3M ago
GNLX
REPL
Premium
The Fly
Genelux initiated with a Buy at Lake Street
3M ago
GNLX
Premium
Company Announcements
Genelux Corp. Lowers Stock Option Exercise Prices
5M ago
8K
GNLX
Premium
Ratings
Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating
5M ago
GNLX
Premium
Ratings
Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position
5M ago
GNLX
Premium
Ratings
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments
5M ago
GNLX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.